Related Experiment Video
Updated: Apr 4, 2026
CD Spectroscopy to Study DNA-Protein Interactions
Published on: February 10, 2022
SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to
Francois Le Loarer1,2,3, Sarah Watson4,5, Gaelle Pierron6
1Cancer Research Center of Lyon, INSERM U1052, Lyon, France.
Abstract:
While investigating cohorts of unclassified sarcomas by RNA sequencing, we identified 19 cases with inactivation of SMARCA4, which encodes an ATPase subunit of BAF chromatin-remodeling complexes. Clinically, the cases were all strikingly similar, presenting as compressive mediastino-pulmonary masses in 30- to 35-year-old adults with a median survival time of 7 months. To help define the nosological relationships of these tumors, we compared their transcriptomic profiles with those of SMARCA4-mutated small-cell carcinomas of the ovary, hypercalcemic type (SCCOHTs), SMARCB1-inactivated malignant rhabdoid tumors (MRTs) and lung carcinomas (of which 10% display SMARCA4 mutations). Gene profiling analyses demonstrated that these tumors were distinct from lung carcinomas but related to MRTs and SCCOHTs. Transcriptome analyses, further validated by immunohistochemistry, highlighted strong expression of SOX2, a marker that supports the differential diagnosis of these tumors from SMARCA4-deficient lung carcinomas. The prospective recruitment of cases confirmed this new category of 'SMARCA4-deficient thoracic sarcomas' as readily recognizable in clinical practice, providing opportunities to tailor their therapeutic management.
Insights
Researchers identified a new category of thoracic sarcomas defined by SMARCA4 gene mutations. These tumors present similarly in adults and are distinct from lung cancers, aiding diagnosis and treatment.
Area of Science:
- Oncology
- Genetics
- Pathology
Background:
- SMARCA4 gene mutations are found in various cancers.
- Unclassified sarcomas often present diagnostic challenges.
Purpose of the Study:
- To define the characteristics and nosological relationships of SMARCA4-deficient thoracic sarcomas.
- To establish diagnostic markers for this new tumor category.
Main Methods:
- RNA sequencing of unclassified sarcomas.
- Transcriptomic profiling and comparison with related tumor types.
- Immunohistochemistry for SOX2 expression.
Main Results:
- Identified 19 cases of SMARCA4-deficient thoracic sarcomas.
- These tumors are clinically similar, presenting as mediastino-pulmonary masses.
- Transcriptomic data showed distinctness from lung carcinomas but relation to MRTs and SCCOHTs.
- Strong SOX2 expression aids differential diagnosis.
Conclusions:
- Established 'SMARCA4-deficient thoracic sarcomas' as a recognizable clinical entity.
- SOX2 expression is a key diagnostic marker.
- This classification facilitates tailored therapeutic management.
More Related Videos
07:49Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
06:44Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
Published on: March 1, 2024
Related Concept Videos
02:23Abnormal Proliferation
02:23Master Transcription Regulators
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:12Loss of Tumor Suppressor Gene Functions
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...